Bilateral Breast Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: BLT006 MIFTS: 48	Bilateral Breast Cancer Categories: Cancer diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Bilateral Breast Cancer

MalaCards integrated aliases for Bilateral Breast Cancer:

Name: Bilateral Breast Cancer ¹¹ ⁵³ ⁵ ¹⁴ ⁷¹

Bilateral Breast Carcinoma ¹¹ ⁵

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:6741

NCIt ⁴⁹ C8287

UMLS ⁷¹ C0281267

Sources

Summaries for Bilateral Breast Cancer

Disease Ontology: ¹¹ A breast carcinoma that is characterized by an individual having breast cancer in both breasts, either simultaneously or at different times.

MalaCards based summary: Bilateral Breast Cancer, also known as bilateral breast carcinoma, is related to breast-ovarian cancer, familial 2 and telangiectasis. An important gene associated with Bilateral Breast Cancer is BRCA2 (BRCA2 DNA Repair Associated), and among its related pathways/superpathways are Gene expression (Transcription) and ERK Signaling. The drugs Adenosine and Tucatinib have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and prostate, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Decreased viability

Sources

Related Diseases for Bilateral Breast Cancer

Diseases related to Bilateral Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 412)

#	Related Disease	Score	Top Affiliating Genes
1	breast-ovarian cancer, familial 2	30.6	BRCA2 BRCA1
2	telangiectasis	30.4	TP53 CHEK2 ATM
3	gynecomastia	30.4	PGR ESR1 ERBB2
4	hereditary breast cancer	30.3	PALB2 CHEK2 CDH1 BRCA2 BRCA1
5	breast-ovarian cancer, familial 1	30.3	RAD51C PALB2 BRCA2 BRCA1
6	ataxia-telangiectasia	30.1	TP53 RAD51 CHEK2 BRCA2 BRCA1 ATM
7	neurofibromatosis, type i	30.1	TP53 MLH1 CDKN2A BRCA2
8	breast mucinous carcinoma	30.1	PGR ERBB2
9	breast squamous cell carcinoma	30.0	PGR ESR1 ERBB2
10	cervical adenocarcinoma	30.0	TP53 PGR ESR1 CDKN2A
11	mammary paget's disease	30.0	PGR ESR1 ERBB2
12	ovarian cancer 1	29.9	RAD51C PALB2 BRCA2 BRCA1
13	ovarian carcinosarcoma	29.9	TP53 ERBB2 BRCA2 BRCA1
14	tubular adenocarcinoma	29.8	PGR ESR1 ERBB2 CDH1
15	carcinosarcoma	29.8	TP53 PGR ERBB2 CDKN2A CDH1
16	mucinous adenocarcinoma	29.8	TP53 MLH1 ERBB2 CDKN2A
17	esophagus adenocarcinoma	29.8	TP53 ERBB2 CDKN2A CDH1
18	osteogenic sarcoma	29.8	TP53 ESR1 CHEK2 CDKN2A
19	breast disease	29.7	TP53 PGR FHIT ESR1 ERBB2 BRCA2
20	breast metaplastic carcinoma	29.7	TP53 PGR ESR1 ERBB2
21	ductal carcinoma in situ	29.7	TP53 PGR ESR1 ERBB2 CDKN2A CDH1
22	gastrointestinal stromal tumor	29.6	TP53 ESR1 ERBB2 CDKN2A
23	endometrial adenocarcinoma	29.6	TP53 PGR MLH1 ESR1 CDKN2A
24	comedo carcinoma	29.6	TP53 PGR ESR1 ERBB2 BRCA2
25	head and neck cancer	29.6	TP53 ERBB2 CDKN2A CDH1
26	female breast cancer	29.6	TP53 PGR MLH1 ESR1 ERBB2 CDKN2A
27	synchronous bilateral breast carcinoma	29.5	TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
28	deficiency anemia	29.5	TP53 RAD51 PALB2 BRCA2 BRCA1 ATM
29	lobular neoplasia	29.5	TP53 PGR PALB2 ESR1 ERBB2 CDH1
30	papillary serous adenocarcinoma	29.5	TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
31	breast fibroadenoma	29.4	TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
32	adenocarcinoma	29.4	TP53 MLH1 ERBB2 CDKN2A CDH1 BRCA2
33	squamous cell carcinoma	29.3	TP53 GSTP1 FHIT ERBB2 CHEK2 CDKN2A
34	breast ductal carcinoma	29.3	TP53 PGR ESR1 ERBB2 CDH1 BRCA2
35	cowden syndrome 1	29.3	TP53 PALB2 MLH1 CHEK2 BRCA2 BRCA1
36	adenoid cystic carcinoma	29.2	TP53 PGR ERBB2 CHEK2 CDKN2A CDH1
37	inherited cancer-predisposing syndrome	28.9	TP53 RAD51D RAD51C PALB2 MLH1 CHEK2
38	bap1 tumor predisposition syndrome	28.9	TP53 RAD51D RAD51C PALB2 MLH1 CHEK2
39	wilms tumor 1	28.7	TP53 PGR PALB2 ESR1 ERBB2 CHEK2
40	gastric cancer	28.7	TP53 MLH1 GSTP1 FHIT ESR1 ERBB2
41	esophageal cancer	28.6	TP53 MLH1 GSTP1 FHIT ESR1 ERBB2
42	serous cystadenocarcinoma	28.3	TP53 RAD51D RAD51C PGR MLH1 ESR1
43	endometrial cancer	28.1	TP53 RAD51 PGR MLH1 GSTP1 FHIT
44	hereditary breast ovarian cancer syndrome	28.1	TP53 RAD51D RAD51C RAD51 PGR PALB2
45	aplastic anemia	28.1	TP53 RAD51D RAD51C RAD51 PALB2 MLH1
46	diffuse gastric and lobular breast cancer syndrome	28.0	TP53 RAD51D RAD51C PALB2 MLH1 ERBB2
47	sporadic breast cancer	27.9	TP53 RAD51C RAD51 PGR PALB2 FHIT
48	breast cancer	27.9	TP53 RAD51D RAD51C RAD51 PGR PALB2
49	li-fraumeni syndrome	27.9	TP53 RAD51D RAD51C RAD51 PALB2 MLH1
50	lung cancer	27.9	TP53 RAD51 PALB2 MLH1 GSTP1 FHIT

Graphical network of the top 20 diseases related to Bilateral Breast Cancer:

Sources

Symptoms & Phenotypes for Bilateral Breast Cancer

GenomeRNAi Phenotypes related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

²⁵ (show all 41)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	10.65	BARD1 BRCA1 BRCA2 CDKN2A MLH1 PALB2
2	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	10.65	ATM BRCA1 BRCA2 CDKN2A MLH1 PALB2
3	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-3	10.65	ATM BARD1 BRCA1 BRCA2 CHEK2 MLH1
4	Decreased viability	GR00221-A-1	10.61	CDKN2A ESR1
5	Decreased viability	GR00221-A-2	10.61	CHEK2 ESR1 BRCA1
6	Decreased viability	GR00221-A-3	10.61	ATM CDKN2A CHEK2 ERBB2 BRCA1
7	Decreased viability	GR00221-A-4	10.61	ATM CDKN2A CHEK2 ERBB2 ESR1
8	Decreased viability	GR00301-A	10.61	BRCA1
9	Decreased viability	GR00342-S-2	10.61	CHEK2
10	Decreased viability	GR00386-A-1	10.61	ESR1
11	Decreased viability	GR00402-S-2	10.61	ESR1
12	Decreased homologous recombination repair frequency	GR00151-A-1	10.46	BARD1 BRCA1 RAD51
13	Decreased homologous recombination repair frequency	GR00151-A-2	10.46	BRCA1 RAD51
14	Decreased homologous recombination repair frequency	GR00236-A-1	10.46	BARD1 BRCA1 BRCA2 PALB2 RAD51
15	Decreased homologous recombination repair frequency	GR00236-A-2	10.46	BARD1 BRCA1 BRCA2 PALB2 RAD51
16	Decreased homologous recombination repair frequency	GR00236-A-3	10.46	BARD1 BRCA1 BRCA2 PALB2 RAD51
17	no effect	GR00402-S-1	10.17	ATM BARD1 BRCA1 BRCA2 CDH1 CDH13
18	no effect	GR00402-S-2	10.17	ATM BARD1 BRCA1 BRCA2 CDH13 CDKN2A
19	Increased ionizing radiation sensitivity	GR00232-A-1	9.95	ATM BARD1 BRCA1 BRCA2 CDH1 GSTP1
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-1	9.86	CHEK2 MLH1
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-104	9.86	GSTP1
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-107	9.86	GSTP1
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-112	9.86	CHEK2
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-114	9.86	CHEK2
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-120	9.86	CHEK2
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-123	9.86	CHEK2
27	Increased shRNA abundance (Z-score > 2)	GR00366-A-124	9.86	MLH1
28	Increased shRNA abundance (Z-score > 2)	GR00366-A-130	9.86	GSTP1
29	Increased shRNA abundance (Z-score > 2)	GR00366-A-142	9.86	CHEK2
30	Increased shRNA abundance (Z-score > 2)	GR00366-A-195	9.86	MLH1
31	Increased shRNA abundance (Z-score > 2)	GR00366-A-200	9.86	MLH1
32	Increased shRNA abundance (Z-score > 2)	GR00366-A-60	9.86	CHEK2
33	Increased shRNA abundance (Z-score > 2)	GR00366-A-78	9.86	MLH1
34	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	9.86	CHEK2
35	Synthetic lethal with cisplatin	GR00101-A-1	9.81	BARD1 BRCA1 BRCA2 RAD51
36	Decreased viability with cisplatin	GR00101-A-4	9.8	BARD1 BRCA1 BRCA2 RAD51
37	Increased homologous recombination repair frequency	GR00236-A-1	9.56	PGR
38	Increased homologous recombination repair frequency	GR00236-A-2	9.56	PGR
39	Decreased viability after ionizing radiation	GR00232-A-2	9.54	ATM BRCA1 BRCA2
40	Decreased viability in pancreas lineage	GR00235-A	9.5	CHEK2 PGR TP53
41	Increased cell death in HCT116 cells	GR00103-A-0	9.18	RAD51

MGI Mouse Phenotypes related to Bilateral Breast Cancer:

⁴⁵ (show all 15)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	10.48	ATM BARD1 BRCA1 BRCA2 CDH1 CDH13
2	homeostasis/metabolism	MP:0005376	10.42	ATM BARD1 BRCA1 BRCA2 CDH1 CDH13
3	growth/size/body region	MP:0005378	10.38	ATM BARD1 BRCA1 BRCA2 CDH1 CDKN2A
4	endocrine/exocrine gland	MP:0005379	10.33	ATM BARD1 BRCA1 BRCA2 CDH1 CDH13
5	embryo	MP:0005380	10.31	ATM BARD1 BRCA1 BRCA2 CDH1 CDKN2A
6	nervous system	MP:0003631	10.3	ATM BARD1 BRCA1 BRCA2 CDKN2A CHEK2
7	cellular	MP:0005384	10.24	ATM BARD1 BRCA1 BRCA2 CDH1 CDKN2A
8	normal	MP:0002873	10.19	BARD1 BRCA1 BRCA2 CDH1 ERBB2 ESR1
9	limbs/digits/tail	MP:0005371	10.16	BRCA1 BRCA2 ERBB2 ESR1 HIC1 PALB2
10	digestive/alimentary	MP:0005381	10.1	BRCA1 BRCA2 CDH1 CDKN2A ERBB2 ESR1
11	cardiovascular system	MP:0005385	10.1	ATM BRCA1 CDH1 CDH13 CDKN2A CHEK2
12	immune system	MP:0005387	10.03	ATM BRCA1 BRCA2 CDH1 CDKN2A CHEK2
13	reproductive system	MP:0005389	10.03	ATM BARD1 BRCA1 BRCA2 CDH1 CDH13
14	mortality/aging	MP:0010768	9.93	ATM BARD1 BRCA1 BRCA2 CDH1 CDH13
15	integument	MP:0010771	9.5	ATM BRCA1 BRCA2 CDH1 CDH13 CDKN2A

Sources

Drugs & Therapeutics for Bilateral Breast Cancer

Drugs for Bilateral Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 42)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Adenosine

Approved, Investigational

Phase 3

58-61-7

60961

Tucatinib

Approved, Investigational

Phase 3

937263-43-9

51039094

Trastuzumab

Approved, Investigational

Phase 3

180288-69-1

Letrozole

Approved, Investigational

Phase 3

112809-51-5

3902

Exemestane

Approved, Investigational

Phase 3

107868-30-4

60198

Sodium citrate

Approved, Investigational

Phase 3

68-04-2

23431961

Anastrozole

Approved, Investigational

Phase 3

120511-73-1

2187

Tamoxifen

Approved

Phase 3

10540-29-1, 54965-24-1

2733526

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 3

77-92-9

311

Ado-Trastuzumab Emtansine

Phase 3

Antineoplastic Agents, Immunological

Phase 3

Maytansine

Phase 3

Protein Kinase Inhibitors

Phase 3

Estrogens

Phase 3

Antineoplastic Agents, Hormonal

Phase 3

Estrogen Receptor Modulators

Phase 3

Estrogen Receptor Antagonists

Phase 3

Estrogen Antagonists

Phase 3

Hormones

Phase 3

Hormone Antagonists

Phase 3

Aromatase Inhibitors

Phase 3

Citrate

Phase 3

Selective Estrogen Receptor Modulators

Phase 3

Levoleucovorin

Approved, Experimental, Investigational

Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Sargramostim

Approved, Investigational

Phase 2

123774-72-1

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 2

59-30-3

6037

Molgramostim

Investigational

Phase 2

99283-10-0

Folate

Phase 2

Alkylating Agents

Phase 2

Vaccines

Phase 2

Antirheumatic Agents

Phase 2

Vitamin B9

Phase 2

Antineoplastic Agents, Alkylating

Phase 2

Vitamin B Complex

Phase 2

Immunosuppressive Agents

Phase 2

Immunologic Factors

Phase 2

Antimitotic Agents

Phase 2

Tubulin Modulators

Phase 2

Epothilones

Phase 2

Epothilone B

Phase 2

4456137

Progesterone

Approved, Vet_approved

Phase 1

57-83-0

5994

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib	Recruiting	NCT04457596	Phase 3	Placebo Administration;Tucatinib
2	A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer	Active, not recruiting	NCT01272037	Phase 3	Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
3	Volumetric Lumpectomy Specimen Image Visualization for Intraoperatively Directing Cavity Shaves, a Phase II Study (VIVID)	Recruiting	NCT05545150	Phase 2
4	Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer	Active, not recruiting	NCT03012100	Phase 2	Cyclophosphamide
5	A Phase II Randomized Study of Ixabepilone vs. Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2/Neu-Negative Breast Cancer	Active, not recruiting	NCT00877500	Phase 2	Ixabepilone
6	A Phase 1b Study of Berzosertib in Combination With Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer	Recruiting	NCT04052555	Phase 1	Berzosertib
7	Genome-Wide Association Study of Radiation Exposure and Bilateral Breast Cancer	Active, not recruiting	NCT00903591

Search NIH Clinical Center for Bilateral Breast Cancer

Sources

Genetic Tests for Bilateral Breast Cancer

Sources

Anatomical Context for Bilateral Breast Cancer

Organs/tissues related to Bilateral Breast Cancer:

MalaCards : Breast, Lymph Node, Prostate, Skin, Ovary, Cervix, Bone Marrow

Sources

Publications for Bilateral Breast Cancer

Articles related to Bilateral Breast Cancer:

(show top 50) (show all 943)

#	Title	Authors	PMID	Year
1	A novel BRCA2 mutation that segregates with breast and prostate cancer in a Spanish family. ⁵³ ⁶²	Salgado J...Garcia-Foncillas J	19288190	2010
2	A novel de novo BRCA2 mutation of paternal origin identified in a Spanish woman with early onset bilateral breast cancer. ⁵³ ⁶²	Diez O...Balmana J	19649703	2010
3	Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. ⁵³ ⁶²	Borg A...Bernstein JL	20104584	2010
4	Robotic resection of intraductal neoplasm of the pancreas. ⁵³ ⁶²	Machado MA...Abdalla RZ	19698031	2009
5	A novel deletion of BRCA1 gene that eliminates the ATG initiation codon without affecting the promoter region. ⁵³ ⁶²	Marino M...Calandra S	19393826	2009
6	Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. ⁵³ ⁶²	Flanagan JM...Petronis A	19153073	2009
7	Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer. ⁵³ ⁶²	Skasko E...Pienkowski T	19372713	2009
8	Accuracy of the BRCAPRO model among women with bilateral breast cancer. ⁵³ ⁶²	Ready KJ...Arun B	19127556	2009
9	Identification of a de novo BRCA1 mutation in a woman with early onset bilateral breast cancer. ⁵³ ⁶²	Edwards E...Eccles D	19629752	2009
10	Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer. ⁵³ ⁶²	Schrauder M...Fasching PA	18264724	2008
11	Altered DNA binding by the human Rad51-R150Q mutant found in breast cancer patients. ⁵³ ⁶²	Ishida T...Kurumizaka H	17666788	2007
12	[Analysis of the mutation of BRCA1 gene in 70 Uigur women breast cancer patients in Xinjiang]. ⁵³ ⁶²	Fu XG...Pang LJ	17557253	2007
13	Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. ⁵³ ⁶²	Gronwald J...Hereditary Breast Cancer Clinical Study Group	16331614	2006
14	Association of common ATM polymorphism with bilateral breast cancer. ⁵³ ⁶²	Heikkinen K...Winqvist R	15756685	2005
15	A comparison of bilateral breast cancers in BRCA carriers. ⁵³ ⁶²	Weitzel JN...Narod SA	15941968	2005
16	BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients. ⁵³ ⁶²	Rogozinska-Szczepka J...Wojciechowska-Lacka A	15319244	2004
17	ATM variants 7271T>G and IVS10-6T>G among women with unilateral and bilateral breast cancer. ⁵³ ⁶²	Bernstein JL...WECARE Study Collaborative Group	14562025	2003
18	Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. ⁵³ ⁶²	Bernstein JL...WECARE Study Collaborative Group	12673797	2003
19	Sex hormone-binding globulin polymorphisms in familial and sporadic breast cancer. ⁵³ ⁶²	Forsti A...Hemminki K	12151349	2002
20	Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing. ⁵³ ⁶²	de la Hoya M...Caldes T	11802208	2002
21	BRCA1 and BRCA2 mutations in Russian familial breast cancer. ⁵³ ⁶²	Tereschenko IV...Pharoah PD	11793480	2002
22	Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer. ⁵³ ⁶²	Steinmann D...Dork T	11556836	2001
23	BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age. ⁵³ ⁶²	Bergthorsson JT...Niebuhr E	11389159	2001
24	Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families. ⁵³ ⁶²	Ikeda N...Noguchi S	11149425	2001
25	Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. ⁵³ ⁶²	Narod SA...Hereditary Breast Cancer Clinical Study Group	11130383	2000
26	Frequency of germ-line BRCA1 mutations among Spanish families from a Mediterranean area. ⁵³ ⁶²	Blesa JR...Ochoa E	10737987	2000
27	Detection of BRCA1 and BRCA2 mutations in breast cancer families by a comprehensive two-stage screening procedure. ⁵³ ⁶²	Spitzer E...Grosse R	10699917	2000
28	Identification of Rad51 alteration in patients with bilateral breast cancer. ⁵³ ⁶²	Kato M...Miki Y	10807537	2000
29	BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer. ⁵³ ⁶²	Gershoni-Baruch R...Robinson E	10573018	1999
30	Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2. ⁵³ ⁶²	Ligtenberg MJ...Van 't Veer LJ	10188893	1999
31	BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. ⁵³ ⁶²	Shattuck-Eidens D...Thomas A	9333265	1997
32	BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. ⁵³ ⁶²	Couch FJ...Weber BL	9145677	1997
33	Abnormal FHIT transcripts in human breast carcinomas: a clinicopathological and epidemiological analysis of 61 Japanese cases. ⁵³ ⁶²	Hayashi S...Nakachi K	9157994	1997
34	Germline mutation of BRCA1 in Japanese breast cancer families. ⁵³ ⁶²	Inoue R...Nagao M	7627958	1995
35	Estrogen and progesterone receptor content in bilateral breast cancer. ⁵³ ⁶²	Brankovic-Magic M...Spuzic I	7651928	1995
36	Genetic analysis of the BRCA1 region in a large breast/ovarian family: refinement of the minimal region containing BRCA1. ⁵³ ⁶²	Kelsell DP...Spurr NK	8281142	1993
37	Bilateral breast cancer: one disease or two? ⁵³ ⁶²	Dawson PJ...Wolman SR	1663803	1991
38	Clinical application of artificial neural network (ANN) modeling to predict BRCA1/2 germline deleterious variants in Chinese bilateral primary breast cancer patients. ⁶²	Li Y...Fu F	36324133	2022
39	Long-term survival of screen-detected synchronous and metachronous bilateral non-palpable breast cancer among Chinese women: a hospital-based study (2003-2017). ⁶²	Pan B...Sun Q	36166112	2022
40	Concurrent Pathogenic Variants of BRCA1, MUTYH and CHEK2 in a Hereditary Cancer Family. ⁶²	Agaoglu NB...Rana HQ	36368126	2022
41	Comparison of 68 Ga-FAPI PET and 18 F-FDG PET Findings in a Patient With Bilateral Breast Cancer of 2 Different Histopathologies. ⁶²	Choudhury S...Rangarajan V	35695729	2022
42	A novel germline mutation of TP53 with breast cancer diagnosed as Li-Fraumeni syndrome. ⁶²	Kai M...Nakamura M	36219266	2022
43	Cystic degeneration during neo-adjuvant chemotherapy predicts squamous metaplasia of triple negative breast cancer: report of two cases. ⁶²	Inoue M...Oyama T	36186230	2022
44	Surgical Management and Contralateral Breast Cancer Risk in Women with History of Radiation Therapy for Hodgkin Lymphoma: Results from a Population-Based Cohort. ⁶²	Eisenberg ER...Wong SM	35668306	2022
45	HBOC syndrome with an uncharacterized variant in the BRCA1 gene in a patient diagnosed with endometrial cancer after surgery for bilateral breast cancer: A case report. ⁶²	Mabuchi Y...Ino K	35949594	2022
46	Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial. ⁶²	Vliek SB...Linn SC	35442755	2022
47	Management of Crohn's disease relapse during neoadjuvant chemotherapy for bilateral breast cancer: a case report. ⁶²	Yamada M...Sasajima Y	36176955	2022
48	Is laterality in breast Cancer still worth studying? Local experience in Bahrain. ⁶²	Al Saad S...Yaghan R	36088284	2022
49	Synchronous bilateral chest wall irradiation with regional nodal irradiation: A literature review of techniques and a case study. ⁶²	Protopapa M...Platoni K	35961182	2022
50	Retraction notice to "Bilateral breast cancer resection performed under the bilateral transversus thoracic muscle plane block" [J. Clin. Anesth. 33(2016)413]. ⁶²	Ueshima H...Otake H	35393183	2022

Sources

Genes for Bilateral Breast Cancer

Genes related to Bilateral Breast Cancer (2 elite genes):

(show all 23)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	BRCA2	BRCA2 DNA Repair Associated	Protein Coding	427.28	Pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11556836 10573018 19649703 (more) 19372713 15319244 19127556 11793480 10699917 11389159 19153073 11802208 11149425 20104584 10188893 16331614 19288190 11130383 19698031
2	BRCA1	BRCA1 DNA Repair Associated	Protein Coding	427.22	Pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11556836 10573018 17557253 (more) 19372713 8723683 15319244 10737987 9145677 19629752 8281142 19736894 19153073 11802208 11389159 11149425 20104584 10188893 19649703 16331614 12151349 9333265 7627958 11130383 19127556 19393826
3	ATM	ATM Serine/Threonine Kinase	Protein Coding	22.25	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19153073 12673797 14562025 (more) 15756685 18264724
4	CHEK2	Checkpoint Kinase 2	Protein Coding	21.96	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19372713
5	RAD51	RAD51 Recombinase	Protein Coding	17.68	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17666788 10807537
6	FHIT	Fragile Histidine Triad Diadenosine Triphosphatase	Protein Coding	15.35	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9157994
7	PGR	Progesterone Receptor	Protein Coding	14.51	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7651928
8	ESR1	Estrogen Receptor 1	Protein Coding	13.13	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1663803 15941968 19153073
9	MLH1	MutL Homolog 1	Protein Coding	12.24	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
10	CDH1	Cadherin 1	Protein Coding	11.29	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	10.94	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
12	HIC1	HIC ZBTB Transcriptional Repressor 1	Protein Coding	9.73	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
13	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	7.93	DISEASES inferred ¹⁴
14	PALB2	Partner And Localizer Of BRCA2	Protein Coding	7.24	DISEASES inferred ¹⁴
15	CDH13	Cadherin 13	Protein Coding	6.9	GeneCards inferred via : Publications (show sections)
16	GSTP1	Glutathione S-Transferase Pi 1	Protein Coding	6.9	GeneCards inferred via : Publications (show sections)
17	RAD51C	RAD51 Paralog C	Protein Coding	6.53	DISEASES inferred ¹⁴
18	TP53	Tumor Protein P53	Protein Coding	6.52	DISEASES inferred ¹⁴
19	RAD51D	RAD51 Paralog D	Protein Coding	6.51	DISEASES inferred ¹⁴
20	BARD1	BRCA1 Associated RING Domain 1	Protein Coding	6.09	DISEASES inferred ¹⁴
21	PTEN	Phosphatase And Tensin Homolog	Protein Coding	5.76	DISEASES inferred ¹⁴
22	CYP19A1	Cytochrome P450 Family 19 Subfamily A Member 1	Protein Coding	5.53	DISEASES inferred ¹⁴
23	STK11	Serine/Threonine Kinase 11	Protein Coding	5.51	DISEASES inferred ¹⁴

Sources

Variations for Bilateral Breast Cancer

ClinVar genetic disease variations for Bilateral Breast Cancer:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	BRCA1	NM_007294.4(BRCA1):c.1504_1508del (p.Leu502fs)	DEL	Pathogenic	37417	rs80357888	GRCh37: 17:41246040-41246044 GRCh38: 17:43094023-43094027
2	BRCA2	NM_000059.4(BRCA2):c.574dup (p.Met192fs)	DUP	Pathogenic	51926	rs397507802	GRCh37: 13:32900692-32900693 GRCh38: 13:32326555-32326556
3	PALB2	NM_024675.4(PALB2):c.3428T>A (p.Leu1143His)	SNV	Uncertain Significance	126740	rs62625284	GRCh37: 16:23614913-23614913 GRCh38: 16:23603592-23603592
4	SDHB	NM_003000.3(SDHB):c.269G>A (p.Arg90Gln)	SNV	Uncertain Significance	201609	rs570278423	GRCh37: 1:17359572-17359572 GRCh38: 1:17033077-17033077
5	SMARCA4	NM_003072.5(SMARCA4):c.403C>G (p.Pro135Ala)	SNV	Uncertain Significance	238447	rs150949949	GRCh37: 19:11096912-11096912 GRCh38: 19:10986236-10986236
6	MSH6	NM_000179.3(MSH6):c.3727A>T (p.Thr1243Ser)	SNV	Uncertain Significance	127589	rs147453999	GRCh37: 2:48033423-48033423 GRCh38: 2:47806284-47806284
7	ATM	NM_000051.4(ATM):c.2021A>G (p.His674Arg)	SNV	Uncertain Significance	141183	rs201762714	GRCh37: 11:108124663-108124663 GRCh38: 11:108253936-108253936
8	MC1R	NM_002386.4(MC1R):c.104G>A (p.Cys35Tyr)	SNV	Uncertain Significance	430181	rs779504604	GRCh37: 16:89985770-89985770 GRCh38: 16:89919362-89919362

Sources

Expression for Bilateral Breast Cancer

Search GEO for disease gene expression data for Bilateral Breast Cancer.

Sources

Pathways for Bilateral Breast Cancer

Pathways related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 56)

#	Super pathways	Score	Top Affiliating Genes
1	Gene expression (Transcription) ⁶⁶ Show member pathways Generic Transcription Pathway ⁶⁶ RNA Polymerase II Transcription ⁶⁶	14.08	TP53 RAD51D RAD51 PGR MLH1 ESR1
2	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.85	TP53 RAD51 ESR1 ERBB2 CHEK2 CDKN2A
3	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.79	TP53 RAD51D RAD51C RAD51 PALB2 MLH1
4	Cell Cycle, Mitotic ⁶⁶ Show member pathways Cell Cycle ⁶⁶ M Phase ⁶⁶	13.54	TP53 RAD51C RAD51 MLH1 CHEK2 CDKN2A
5	Homology Directed Repair ⁶⁶ Show member pathways Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex ⁶⁶ DNA Double-Strand Break Repair ⁶⁶ DNA Repair ⁶⁶ G2/M DNA damage checkpoint ⁶⁶ HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) ⁶⁶ HDR through MMEJ (alt-NHEJ) ⁶⁶ Processing of DNA double-strand break ends ⁶⁶	13.19	TP53 RAD51D RAD51C RAD51 PALB2 MLH1
6	Regulation of TP53 Activity ⁶⁶ Show member pathways Regulation of TP53 Activity through Association with Co-factors ⁶⁶ Regulation of TP53 Activity through Methylation ⁶⁶ Regulation of TP53 Activity through Phosphorylation ⁶⁶ Transcriptional Regulation by TP53 ⁶⁶	13	TP53 RAD51D MLH1 CHEK2 CDKN2A BRCA1
7	TCR Signaling (Qiagen) ⁶⁴ Show member pathways Fc-EpsilonRI Pathway ⁶⁴ ITK and TCR Signaling ⁶⁴ PDGF Pathway ⁶⁴ PKC-Theta Pathway ⁶⁴	12.96	TP53 RAD51 MLH1 CHEK2 BRCA2 BRCA1
8	Cell Cycle Checkpoints ⁶⁶ Show member pathways G2/M Checkpoints ⁶⁶	12.81	ATM BARD1 BRCA1 CDKN2A CHEK2 TP53
9	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.77	BRCA2 CDH1 CDKN2A ERBB2 FHIT MLH1
10	Meiosis ⁶⁶ Show member pathways Meiotic recombination ⁶⁶ Meiotic synapsis ⁶⁶ Reproduction ⁶⁶	12.76	RAD51C RAD51 MLH1 BRCA2 BRCA1 ATM
11	Malignant pleural mesothelioma ⁷⁴	12.74	TP53 CDKN2A CDH1 BRCA1 BARD1 ATM
12	Homologous DNA Pairing and Strand Exchange ⁶⁶ Show member pathways Defective Base Excision Repair Associated with NEIL1 ⁶⁶ Defective homologous recombination repair (HRR) due to BRCA2 loss of function ⁶⁶ Diseases of Base Excision Repair ⁶⁶ Diseases of DNA Double-Strand Break Repair ⁶⁶ Diseases of DNA repair ⁶⁶ Fanconi anemia pathway ⁶¹ Fanconi Anemia Pathway ⁶⁶ HDR through Homologous Recombination (HRR) ⁶⁶ HDR through Single Strand Annealing (SSA) ⁶⁶ Impaired BRCA2 binding to RAD51 ⁶⁶ Presynaptic phase of homologous DNA pairing and strand exchange ⁶⁶	12.74	ATM BARD1 BRCA1 BRCA2 MLH1 PALB2
13	DNA repair pathways, full network ⁷⁴ Show member pathways Defective Mismatch Repair Associated With MSH2 ⁶⁶ Defective Mismatch Repair Associated With MSH3 ⁶⁶ Defective Mismatch Repair Associated With MSH6 ⁶⁶ Diseases of Mismatch Repair (MMR) ⁶⁶ Dual Incision in GG-NER ⁶⁶ Homologous recombination ⁷⁴ Mismatch Repair ⁶⁶ Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) ⁶⁶ Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) ⁶⁶ Non-homologous end joining ⁷⁴ Nucleotide excision repair ⁷⁴ Nucleotide excision repair in xeroderma pigmentosum ⁷⁴ Nucleotide Excision Repair Pathway ⁶⁴	12.67	RAD51C RAD51 PALB2 MLH1 BRCA2 BRCA1
14	Chks in Checkpoint Regulation ⁶⁴ Show member pathways DNA Repair Mechanisms ⁶⁴ Estrogen-mediated S-Phase Entry ⁶⁴ G2-M Phase Transition ⁶⁴ SREBP Proteolysis ⁶⁴	12.66	TP53 RAD51 ESR1 CHEK2 BRCA2 BRCA1
15	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.45	TP53 ESR1 ERBB2 CDH1
16	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.44	TP53 RAD51 PGR ESR1 ERBB2 BRCA2
17	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.43	TP53 ERBB2 CHEK2 ATM
18	Cell cycle Regulation of G1/S transition (part 1) ²² Show member pathways Cell cycle ESR1 regulation of G1/S transition ²² Cell cycle Role of SCF complex in cell cycle regulation ²² Immune response MIF-JAB1 signaling ²² Mitotic Roles of Polo Like Kinases ⁶⁴	12.43	PGR ESR1 CHEK2 CDKN2A BRCA1
19	DNA Double Strand Break Response ⁶⁶ Show member pathways Nonhomologous End-Joining (NHEJ) ⁶⁶ Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks ⁶⁶ Sensing of DNA Double Strand Breaks ⁶⁶	12.42	TP53 CHEK2 BRCA1 BARD1 ATM
20	DNA Damage ³	12.38	TP53 RAD51 MLH1 GSTP1 CHEK2 CDKN2A
21	Resolution of D-loop Structures through Holliday Junction Intermediates ⁶⁶ Show member pathways Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function ⁶⁶ Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function ⁶⁶ Defective homologous recombination repair (HRR) due to BRCA1 loss of function ⁶⁶ Defective homologous recombination repair (HRR) due to PALB2 loss of function ⁶⁶ Impaired BRCA2 binding to PALB2 ⁶⁶ Resolution of D-Loop Structures ⁶⁶ Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) ⁶⁶	12.31	RAD51D RAD51C RAD51 PALB2 BRCA2 BRCA1
22	Cell cycle ⁷⁴ Show member pathways G1 to S cell cycle control ⁷⁴	12.27	TP53 CHEK2 CDKN2A ATM
23	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.23	TP53 CHEK2 BRCA1 ATM
24	miRNA regulation of DNA damage response ⁷⁴ Show member pathways DNA damage response ⁷⁴	12.17	TP53 RAD51 CHEK2 BRCA1 ATM
25	DNA damage response (only ATM dependent) ⁷⁴	11.9	TP53 ERBB2 ATM
26	ATM Pathway ⁶⁴ Show member pathways ATM signaling pathway ⁷⁴	11.87	TP53 RAD51 CHEK2 BRCA1 ATM
27	DNA IR-double strand breaks and cellular response via ATM ⁷⁴ Show member pathways ATM pathway ⁶¹ DNA damage_DNA-damage-induced responses ²²	11.86	ATM BRCA1 BRCA2 CDKN2A CHEK2 RAD51
28	Regulation of TP53 Expression and Degradation ⁶⁶ Show member pathways Regulation of TP53 Degradation ⁶⁶ Regulation of TP53 Expression ⁶⁶	11.82	TP53 CHEK2 CDKN2A ATM
29	Integrated breast cancer pathway ⁷⁴	11.79	TP53 RAD51 ESR1 CHEK2 CDH1 BRCA2
30	E2F transcription factor network ⁶¹	11.76	ATM BRCA1 CDKN2A HIC1
31	Head and neck squamous cell carcinoma ⁷⁴	11.75	TP53 ERBB2 CDKN2A
32	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.73	TP53 ERBB2 BRCA1 ATM
33	AP-1 transcription factor network ⁶¹	11.72	TP53 ESR1 CDKN2A
34	Validated nuclear estrogen receptor alpha network ⁶¹	11.69	PGR ESR1 BRCA1
35	p53 pathway ⁶¹	11.63	TP53 CHEK2 CDKN2A ATM
36	BRCA1 Pathway ⁶⁴ Show member pathways Fanconi's Anaemia Pathway ⁶⁴	11.62	TP53 RAD51 CHEK2 BRCA2 BRCA1 BARD1
37	DNA damage_ATM/ATR regulation of G1/S checkpoint ²²	11.58	TP53 CHEK2 BRCA1 BARD1 ATM
38	Validated transcriptional targets of deltaNp63 isoforms ⁶¹	11.55	CDKN2A BRCA2 ATM
39	Busulfan Pathway, Pharmacodynamics ⁶⁰ Show member pathways Catalytic cycle of mammalian flavin-containing monooxygenases (FMOs) ⁷⁴ Defective FMO3 causes TMAU ⁶⁶ FMO oxidises nucleophiles ⁶⁶	11.52	CHEK2 GSTP1 MLH1
40	Cell cycle Role of 14-3-3 proteins in cell cycle regulation ²² Show member pathways 14-3-3 and Cell Cycle Regulation ⁶⁴	11.52	ATM CHEK2 TP53
41	Bladder cancer ⁷⁴	11.51	TP53 ERBB2 CDKN2A CDH1
42	Integrated cancer pathway ⁷⁴	11.47	TP53 CHEK2 BRCA1 BARD1 ATM
43	FOXM1 transcription factor network ⁶¹	11.46	BRCA2 CDKN2A CHEK2 ESR1
44	Ovarian infertility ⁷⁴	11.46	ATM MLH1 PGR RAD51
45	miRNA regulation of p53 pathway in prostate cancer ⁷⁴	11.37	TP53 CHEK2 ATM
46	Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4) ⁷⁴	11.36	PGR ESR1 ERBB2
47	GADD45 Pathway ⁶⁴	11.36	TP53 BRCA1 ATM
48	BARD1 signaling events ⁶¹	11.34	ATM BARD1 BRCA1 RAD51 TP53
49	DNA IR-damage and cellular response via ATR ⁷⁴	11.18	TP53 RAD51 PALB2 MLH1 CHEK2 BRCA2
50	TP53 network ⁷⁴ Show member pathways Activation, translocation and oligomerization of BAX ⁶⁶	11.14	TP53 CDKN2A ATM

Sources

GO Terms for Bilateral Breast Cancer

Cellular components related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

(show all 14)

#	Name	GO ID	Score	Top Affiliating Genes
1	nucleus	GO:0005634	10.68	ATM BARD1 BRCA1 BRCA2 CDKN2A CHEK2
2	nucleoplasm	GO:0005654	10.57	ATM BARD1 BRCA1 BRCA2 CDKN2A CHEK2
3	microtubule organizing center	GO:0005815	9.99	TP53 RAD51D RAD51 BRCA2 ATM
4	chromosome, telomeric region	GO:0000781	9.96	ATM BRCA2 CHEK2 RAD51 RAD51D
5	replication fork	GO:0005657	9.85	TP53 RAD51D RAD51C
6	BRCA1-C complex	GO:0070533	9.84	BRCA1 BARD1
7	condensed nuclear chromosome	GO:0000794	9.83	RAD51 MLH1 BRCA1
8	BRCA1-BARD1 complex	GO:0031436	9.8	BARD1 BRCA1
9	Rad51B-Rad51C-Rad51D-XRCC2 complex	GO:0033063	9.78	RAD51C RAD51D
10	BRCA1-B complex	GO:0070532	9.76	BARD1 BRCA1
11	lateral element	GO:0000800	9.63	RAD51 BRCA2 BRCA1
12	condensed chromosome	GO:0000793	9.62	RAD51 MLH1 BRCA1
13	DNA repair complex	GO:1990391	9.56	PALB2 BRCA2 BRCA1 ATM
14	nuclear ubiquitin ligase complex	GO:0000152	9.23	RAD51 BRCA2 BRCA1 BARD1

Biological processes related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

(show all 37)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of DNA-templated transcription	GO:0045893	10.48	TP53 ESR1 CHEK2 CDKN2A CDH1 BRCA2
2	positive regulation of gene expression	GO:0010628	10.36	TP53 PGR ERBB2 CDKN2A BRCA1 ATM
3	regulation of cell cycle	GO:0051726	10.34	TP53 RAD51D CDKN2A BRCA1 BARD1 ATM
4	double-strand break repair	GO:0006302	10.21	TP53 CHEK2 BRCA2 BRCA1 ATM
5	protein autoubiquitination	GO:0051865	10.19	RAD51 BRCA2 BRCA1 BARD1
6	cell cycle	GO:0007049	10.18	ATM BRCA1 BRCA2 CDKN2A CHEK2 MLH1
7	cellular senescence	GO:0090398	10.15	TP53 CDKN2A BRCA2 ATM
8	somitogenesis	GO:0001756	10.13	ATM PALB2 TP53
9	cellular response to gamma radiation	GO:0071480	10.13	TP53 RAD51 CHEK2 ATM
10	cellular response to ionizing radiation	GO:0071479	10.13	TP53 RAD51 BRCA2 BRCA1 BARD1
11	replicative senescence	GO:0090399	10.1	TP53 CHEK2 CDKN2A ATM
12	intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	GO:0042771	10.09	BRCA2 CHEK2 TP53
13	histone H2A monoubiquitination	GO:0035518	10.08	BARD1 BRCA1 BRCA2 RAD51
14	response to X-ray	GO:0010165	10.06	TP53 RAD51 BRCA2
15	regulation of DNA damage checkpoint	GO:2000001	10.06	RAD51 BRCA2 BRCA1 BARD1
16	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	GO:0006977	10.04	TP53 CHEK2 ATM
17	signal transduction in response to DNA damage	GO:0006975	10.02	CHEK2 ATM
18	signal transduction in response to DNA damage	GO:0042770	10.02	CHEK2 ATM
19	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	GO:0006978	10.01	BRCA2 CHEK2 TP53
20	telomere maintenance via recombination	GO:0000722	10.01	RAD51D RAD51C RAD51 BRCA2
21	response to gamma radiation	GO:0010332	10	TP53 CHEK2 BRCA2
22	intrinsic apoptotic signaling pathway in response to DNA damage	GO:0008630	10	MLH1 HIC1 CHEK2 BRCA2 BRCA1 ATM
23	double-strand break repair via homologous recombination	GO:0000724	10	ATM BRCA1 BRCA2 PALB2 RAD51 RAD51C
24	DNA strand resection involved in replication fork processing	GO:0110025	9.97	BRCA1 BARD1
25	DNA recombination	GO:0006310	9.97	BRCA1 BRCA2 PALB2 RAD51 RAD51C RAD51D
26	reciprocal meiotic recombination	GO:0007131	9.97	RAD51D RAD51C RAD51 MLH1 ATM
27	cellular response to indole-3-methanol	GO:0071681	9.94	CDH1 BRCA1
28	positive regulation of RNA polymerase II transcription preinitiation complex assembly	GO:0045899	9.93	TP53 ESR1
29	strand invasion	GO:0042148	9.93	RAD51D RAD51
30	chromosome organization	GO:0051276	9.91	TP53 RAD51D BRCA2
31	mitotic recombination-dependent replication fork processing	GO:1990426	9.9	RAD51 BRCA2
32	chromosome organization involved in meiotic cell cycle	GO:0070192	9.83	RAD51 ATM
33	DNA metabolic process	GO:0006259	9.83	RAD51D RAD51C RAD51
34	DNA repair	GO:0006281	9.83	RAD51D RAD51C RAD51 PALB2 MLH1 CHEK2
35	chordate embryonic development	GO:0043009	9.82	BRCA2 BRCA1
36	negative regulation of immature T cell proliferation in thymus	GO:0033088	9.82	ERBB2 CDKN2A
37	cellular response to DNA damage stimulus	GO:0006974	9.55	TP53 RAD51D RAD51C RAD51 PALB2 MLH1

Molecular functions related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	DNA binding	GO:0003677	10.13	ATM BRCA1 BRCA2 CDKN2A ESR1 HIC1
2	enzyme binding	GO:0019899	10.03	TP53 RAD51 PGR MLH1 ESR1 BRCA1
3	nucleotide binding	GO:0000166	10.02	RAD51D RAD51C RAD51 MLH1 FHIT ERBB2
4	identical protein binding	GO:0042802	10.02	ATM BRCA1 BRCA2 CDH1 CDH13 CHEK2
5	single-stranded DNA binding	GO:0003697	9.92	RAD51D RAD51 MLH1 BRCA2
6	ATP-dependent DNA damage sensor activity	GO:0140664	9.23	RAD51D RAD51C RAD51 MLH1